Sequence: RQIKIWFQNRRMKWKK
| Experiment Id | EXP001538 |
|---|---|
| Paper | Intracellular delivery of antiviral shRNA using penetratin-based complexes effectively inhibits resp |
| Peptide | Penetratin (PEN) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | Not reported (prepared at penetratin:plasmid molar ratio 20:1) |
| Rna Concentration | Not reported |
| Mixing Ratio | molar ratio 20:1 (penetratin:plasmid) |
| Formulation Format | noncovalent CPP/DNA complexes (electrostatic) |
| Formulation Components | Penetratin + pGFP-V-RS scrambled shRNA plasmid |
| Size Nm | 164.00 |
| Zeta Mv | 8.70 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HEp-2 infected with RSV A2 (MOI 0.1) |
| Animal Model | |
| Administration Route | |
| Output Type | Control (transfection efficiency by GFP; antiviral readouts compared with F-shRNA) |
| Output Value | High transfection efficiency reported for penetratin-scramble (~93.91% at 48 h); no sequence-specific antiviral effect expected/used as negative control |
| Output Units | |
| Output Notes | Scramble control used to demonstrate sequence-specific inhibition by F-shRNA in HEp-2 assays. |
| Toxicity Notes | No significant cytotoxicity vs untreated in HEp-2 (MTT) for penetratin-scramble (20:1 and 25:1) up to 72 h. |
| Curation Notes |